Kristin Brooks04.14.21
Microbiologics is investing in an additional 650-sq.-ft. Biosafety Level 3 (BSL-3) facility within its existing building at its global headquarters in St. Cloud, MN. This addition follows the recent completion of its first BSL-3 lab at the company’s San Diego, CA facility in August 2020. The additional BSL-3 facility allows for increased capabilities and capacity to provide anti-infective testing, assay development and biomaterial production services for highly infectious pathogens, including COVID-19 and other emerging diseases.
Brad Goskowicz, Microbiologics Chief Executive Officer, said, "Demanding timelines and complex regulatory requirements are prompting pharmaceutical and diagnostic companies to outsource aspects of their R&D and QC functions to a qualified CRMO partner. We’re able to provide end-to-end, highly-collaborative support where and when our clients need it, which enables them bring new products to market rapidly and safety."
Microbiologics is a contract research and manufacturing organization providing antiviral testing and assay development services to support drug, vaccine and medical device development processes from discovery through post-market surveillance. Examples of these specialized assay services include virus neutralization, hemagglutination, immunoassay development within ELISA platforms and Single Radial Immunodiffusion (SRID) assays. Microbiologics is currently transferring a SARS-CoV-2 virus neutralization assay for the U.S. Biomedical Advanced Research and Development Authority (BARDA).
Brad Goskowicz, Microbiologics Chief Executive Officer, said, "Demanding timelines and complex regulatory requirements are prompting pharmaceutical and diagnostic companies to outsource aspects of their R&D and QC functions to a qualified CRMO partner. We’re able to provide end-to-end, highly-collaborative support where and when our clients need it, which enables them bring new products to market rapidly and safety."
Microbiologics is a contract research and manufacturing organization providing antiviral testing and assay development services to support drug, vaccine and medical device development processes from discovery through post-market surveillance. Examples of these specialized assay services include virus neutralization, hemagglutination, immunoassay development within ELISA platforms and Single Radial Immunodiffusion (SRID) assays. Microbiologics is currently transferring a SARS-CoV-2 virus neutralization assay for the U.S. Biomedical Advanced Research and Development Authority (BARDA).